- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03802084
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor
A Phase 1b/2a, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Imatinib in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Desmoid tumor (aggressive fibromatosis) is a mesenchymal neoplasm associated with mutations, resulting in -catenin-mediated transcriptional activation. It is composed of a clonal proliferation of mesenchymal, fibroblast-like cells occurred sporadic or as a part of familial adenomatosis polyposis. This tumor has high local recurrence rate after complete excision (~40%). Therefore, although lacking metastatic capability, patients experience repeated recurrence with attendant severe morbidity. Various systemic therapy using NSAID, cytotoxic agent (doxorubicin and vinblastine), biologic agents (tamoxifen, low-dose interferon), and tyrosine kinase inhibitors (imatinib) are recommended with modest activity. Among them, imatinib has shown promising activity and approved as standard treatment for desmoid tumor. However, still there is modest response (10-15% responses) and further combination strategy is warranted to improve antitumor efficacy.
The transforming growth factor-β (TGF-β) family of cytokines has 33 members in humans, including TGF-β isoforms, activins, bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs). These factors regulate growth, survival, differentiation and migration of cells, and have important roles during embryonal development and in the control of adult tissue homeostasis. During carcinogenesis, TGF-β has a dual role; initially it suppresses tumorigenesis by inducing growth arrest and promoting apoptosis, however, in advanced cancers, where TGF-β often is overexpressed. In addition, TCGA (the cancer genome atlas) pan-cancer also demonstrated high expression of TGF-β responsive signature in desmoid tumor. Regarding the combination, TEW-7197 (vactosertib), a TGF-β inhibitor and imatinib demonstrated synergistic effect in vitro and xenograft model. Compared to imatinib alone, administration of imatinib plus vactosertib to mice significantly delayed disease relapse and prolonged survival. Collectively, these results indicate that vactosertib may be a promising candidate for a new therapeutic strategy.
Based on the background, TGF-β inhibition as a potential therapeutic target for desmoid tumor and convey significant implications for the clinical development. Therefore, investigator will conduct the phase II trial of vactosertib in combined with imatinib in desmoid tumor.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Hyo Song Kim, Ph.D
- Phone Number: 82-2-2228-8124
- Email: hyosong77@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed desmoid tumor (aggressive fibromatosis) not available for local treatment (surgical resection or radiation therapy)
- Eastern Cooperative Oncology Group performance status of 0-1
- Measurable lesion (RECIST 1.1.)
Patients with sufficient organ function according to laboratory findings
- Hemoglobin ≥ 9.0 g/dL
- Neutrophils ≥ 1000 /µL
- Platelets ≥ 75,000/µL
- Total Bilirubin ≤ 1.5 × UNL (upper normal limit): For patients with liver metastases, ≤2
- Serum creatinine ≤1.5 X ULN or > 1.5 X Creatinine Clearance ≥50 mL/min for ULN patients (based on 24-hour urinalysis or Cockroft-Gault Formula calculations)
- AST(SGOT)/ALT(SGPT) ≤ 3.0 × UNL or ≤ 5.0 × UNL (for patients with liver or bone metastases)
- Alkaline Phosphatase (ALP): ≤ 3.0 × UNL or ≤ 5.0 × UNL (for patients with liver or bone metastases)
- All patients must be able to provide a newly acquired tumor biopsy during screening (preferred) or provide an available tumor sample taken ≤3 years prior to screening.
- Subjects must have ejection fraction ≥ 50% and no clinically significant valvular dysfunction
Exclusion Criteria:
- Previous TGF-β inhibitor exposed patient
- Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks
- Any unresolved chronic toxicity greater than grade 2 from previous anticancer therapy.
- Has an active infection requiring systemic therapy
- Uncontrolled intercurrent illness, including symptomatic congestive heart failure (NYHA Class III/IV), uncontrolled hypertension (≥150/90mmHg), unstable angina pectoris or myocardial infarction (≤ 6 months prior to screening), uncontrolled cardiac arrhythmia, cardiac valulopathy
- Uncontrolled or active central nervous system metastasis and/or carcinomatous meningitis
- Child-Pugh B or C liver cirrhosis
- History of another primary malignancy.
- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of investigational product(IP).
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of investigational product(IP).
- Current or prior use of immunosuppressive medication within 14 days before the first investigational product(IP).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vactosertib/imatinib combination
|
Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse event
Time Frame: 4 weeks
|
to evaluate the safety and tolerability
|
4 weeks
|
clinical benefit rate was determined using RECIST 1.1
Time Frame: 16weeks
|
to evaluate antitumor activity by determining progression-free survival
|
16weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Connective Tissue
- Neoplasms, Fibrous Tissue
- Fibroma
- Fibromatosis, Aggressive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
- Vactosertib
Other Study ID Numbers
- 4-2018-0807
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Desmoid Tumor
-
Rabin Medical CenterCompletedDesmoid Fibromatosis | Desmoid | Desmoid Fibromatosis of Skin | Desmoid Neoplasm of Chest Wall | Desmoid Tumor Caused by Somatic Mutation | Aggressive Fibromatoses | Fibromatosis DesmoidIsrael
-
Italian Sarcoma GroupCompletedAdvanced Desmoid Tumor | Advanced ChondrosarcomaItaly
-
Blokhin's Russian Cancer Research CenterNot yet recruitingDesmoid Fibromatosis | Desmoid Tumor | DesmoidRussian Federation
-
Ayala Pharmaceuticals, Inc,Active, not recruitingDesmoid Tumor | DesmoidUnited States, Spain, United Kingdom, Australia, Korea, Republic of, Israel, Belgium, Germany, Netherlands, Italy, Poland
-
Erasmus Medical CenterRadboud University Medical Center; Royal Marsden NHS Foundation Trust; The Netherlands...CompletedDesmoid Tumor | Desmoid-type FibromatosisUnited Kingdom, Netherlands
-
University of Colorado, DenverSpringWorks Therapeutics, Inc.No longer availableNeoplasm | Desmoid TumorUnited States
-
Technische Universität DresdenUniversitätsmedizin Mannheim; SOS Desmoid e.V.RecruitingQuality of Life | Desmoid TumorGermany
-
University Hospital, Strasbourg, FranceRecruiting
-
MaineHealthPfizer; Desmoid Tumor Research FoundationCompleted
Clinical Trials on vactosertib/imatinib combination
-
MedPacto, Inc.Recruiting
-
MedPacto, Inc.CompletedHealthy VolunteersKorea, Republic of
-
MedPacto, Inc.Active, not recruitingMetastatic Gastric CancerKorea, Republic of
-
MedPacto, Inc.Merck Sharp & Dohme LLCActive, not recruitingMetastatic Colorectal Cancer | Gastric Cancer | Gastroesophageal Junction AdenocarcinomaKorea, Republic of
-
Grupo Espanol de Investigacion en SarcomasActive, not recruitingDrug Use | GIST | Drug Toxicity | Metastatic Adult Soft Tissue Sarcoma | Maximum Tolerated DoseSpain
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
MedPacto, Inc.AstraZenecaNot yet recruitingUrothelial Carcinoma Recurrent | Advanced Urothelial CarcinomaUnited States
-
Hark Kyun KimRecruiting